-
Oct 29, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
Rosuvastatin may have lower rates of all-cause mortality, major adverse cardiovascular
events (MACE), and major adverse liver outcomes than atorvastatin, a study found.
To compare the real-world effectiveness and safety of the two statins, researchers conducted an active comparator cohort study using target trial emulation
for data from the China Renal Data System and UK Biobank databases. Results were published
Oct. 29 by Annals of Internal Medicine.
-
Oct 29, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
Broad-spectrum antibiotics were associated with increased risk of adverse drug events
(ADEs) among otherwise healthy outpatient adults treated for community-acquired pneumonia
(CAP), a study found.
Researchers conducted an active comparator new-user cohort study of commercially insured adults ages 18 to 64 years diagnosed with outpatient CAP, evaluated by chest X-ray, and dispensed a same-day oral antibiotic regimen in 2007
through 2019. Follow-up for ADEs ranged from two to 90 days.
-
Oct 29, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
https://immattersacp.org/weekly/archives/2024/10/29/2.htm
I.M. Matters Weekly | Vaccinations | October 29, 2024
Changes include a lower age for starting pneumococcal vaccination and an additional
dose of COVID-19 vaccine in older and immunocompromised patients.
The CDC recently announced updates to its recommendations on pneumococcal and COVID-19
vaccinations.
On Oct.
-
Oct 29, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
https://immattersacp.org/weekly/archives/2024/10/29/1.htm
I.M. Matters Weekly | Stroke | October 29, 2024
The updated guideline from the American Heart Association and American Stroke Association
addresses lifelong stroke prevention and includes new sex-and gender-specific recommendations.
-
Oct 29, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
A 28-year-old woman is evaluated for a 2-month history of sleeplessness. She has had
panhypopituitarism since surgery for a craniopharyngioma at age 15 years. Medical
history includes hypoadrenalism, hypogonadism, and hypothyroidism. She is taking estrogen,
progesterone, hydrocortisone, and levothyroxine.
On physical examination, vital signs are normal. A small atrophic thyroid is noted;
her hands are warm and dry, and no lower extremity edema or tremor is evident.
-
Oct 22, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
An online tool increased caregivers' preparation for decision making about firearms
access for community-dwelling persons with Alzheimer's disease and related dementias
(ADRD), a randomized trial found.
The prospective randomized trial included 500 caregivers between June 2022 and February
2024 and compared the Safety in Dementia (SiD) decision aid with the National Institute on
Aging Home Safety Checklist for Alzheimer's Disease Website, which served as a control.
-
Oct 22, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
https://immattersacp.org/weekly/archives/2024/10/22/1.htm
I.M. Matters Weekly | HIV | October 22, 2024
The 2024 update from the HIV Medicine Association of the Infectious Diseases Society
of America offers more focus on patient-centered HIV care and new recommendations
on immunizations, cancer screening, and sexually transmitted infections, among other
topics.
-
Oct 22, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
Join ACP in celebrating Internal Medicine Day on Monday, Oct. 28, in recognition of
the essential role of internal medicine physicians around the world.
Internal medicine physicians are experts in complexity who serve and lead in many
diverse roles and settings. You are critical thinkers who excel in the most challenging
and dynamic environments and provide compassionate care for patients throughout their
health care journey.
-
Oct 22, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
Methadone was associated with a lower risk of treatment discontinuation for opioid
use disorder (OUD) compared with buprenorphine/naloxone, a study found.
To assess the risk of stopping treatment and mortality among people receiving buprenorphine/naloxone
or methadone for OUD, researchers conducted a population-based retrospective cohort study using linked
health administrative databases in British Columbia, Canada, from January 2010 through
March 2020.
-
Oct 22, 2024 | 
immattersacp.org | Gianna Melillo |Janet Colwell |ACP Internist
MKSAP Answer and Critique
The correct answer is C. Increase carvedilol. This content is available to MKSAP subscribers
as Question 45 in the Cardiovascular Medicine section. More information about MKSAP is available online.
The most appropriate management is to increase the dosage of carvedilol (Option C). This patient has recent-onset heart failure with reduced ejection fraction (HFrEF)
and is undergoing medication titration. β-Blockers should be initiated in all
patients with HFrEF.
